Journal: Clinical and Translational Science

Article Title: FAK mediates hypoxia‐induced pulmonary artery smooth muscle cell proliferation by modulating mitochondrial transcription termination factor 1/cyclin D1

doi: 10.1111/cts.13767

Figure Lengend Snippet: Primer sequences for the study.

Article Snippet: The human FAK, mTERF1, and cyclin D1 primers were designed and synthesized by Sangon Biotech (Shanghai) Ltd., China, and the primer sequences are listed in Table .

Techniques: Sequencing

Journal: Clinical and Translational Science

Article Title: FAK mediates hypoxia‐induced pulmonary artery smooth muscle cell proliferation by modulating mitochondrial transcription termination factor 1/cyclin D1

doi: 10.1111/cts.13767

Figure Lengend Snippet: Effect of FAK and mTERF1 knockdown on the protein and mRNA expression levels of FAK, mTERF1, and cyclin D1 under hypoxic and normal conditions. (a) Representative Western blot images of FAK, mTERF1, and cyclin D1 expression in normal and hypoxia conditions treated with siRNA to FAK or mTERF1. β‐Actin was used as the loading control. (b) Quantifying FAK, cyclin D1, and mTERF1 expression levels in the conditions shown in Western blot analysis. (c) The mRNA levels of FAK, mTERF1, and cyclin D1 treated with siRNA to FAK or mTERF1 in normal and hypoxic conditions * p < 0.05; H, hypoxia; N, normal; NS, no significance.

Article Snippet: The human FAK, mTERF1, and cyclin D1 primers were designed and synthesized by Sangon Biotech (Shanghai) Ltd., China, and the primer sequences are listed in Table .

Techniques: Knockdown, Expressing, Western Blot, Control

Journal: Clinical and Translational Science

Article Title: FAK mediates hypoxia‐induced pulmonary artery smooth muscle cell proliferation by modulating mitochondrial transcription termination factor 1/cyclin D1

doi: 10.1111/cts.13767

Figure Lengend Snippet: Immunofluorescence images for FAK and cyclin D1 staining on HPASMCs treated with siRNA to FAK in normal and hypoxia conditions. (a) The immunofluorescence staining image of FAK; (b) The immunofluorescence staining image of cyclin D1. (c) Quantitation of FAK and cyclin D1 expression levels, as shown in immunofluorescence staining. * p < 0.05; H, hypoxia; HPASMCs, human pulmonary artery smooth muscle cells; N, normal.

Article Snippet: The human FAK, mTERF1, and cyclin D1 primers were designed and synthesized by Sangon Biotech (Shanghai) Ltd., China, and the primer sequences are listed in Table .

Techniques: Immunofluorescence, Staining, Quantitation Assay, Expressing

Journal: Current Issues in Molecular Biology

Article Title: Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation

doi: 10.3390/cimb45030164

Figure Lengend Snippet: Effect of K-Ras depletion on G2 cyclin transcription. Graph showing an example of the decrease observed in G2 cyclin transcript when K-Ras or cyclin D is depleted. Cyclin B transcript levels after depletion with K-Ras are significantly lower than in non-targeting controls and after depletion with cyclin D ( p < 0.001, Mann–Whitney U test, standard deviation used as error bar). Cyclin A levels are also significantly lower after depletion of K-Ras than with no depletion; however, there was an equivalent decrease after cyclin D depletion.

Article Snippet: The qPCR was then performed using K-Ras, Cyclin D, and GAPDH primers (Qiagen Ltd, Manchester, UK), using the Roche cyber green system on the Roche light cycler following the manufacturer’s instructions.

Techniques: MANN-WHITNEY, Standard Deviation

Journal: Scientific Reports

Article Title: Potential anti-proliferative activity of Salix mucronata and Triticum spelta plant extracts on liver and colorectal cancer cell lines

doi: 10.1038/s41598-023-30845-z

Figure Lengend Snippet: The effect of different aqueous, 100% EE and 50% EE Salix mucronata and Tritticum spelta plant extracts treated HepG2 and Caco-2 cancer cell lines on P53 , BCL2 and Cyclin D expression level ( A ) p53 expression level in treated HepG2 cancer cell line ( B ) BCL2 expression level in treated HepG2 cancer cell line ( C ) Cyclin D expression level in treated HepG2 cancer cell line ( D ) p53 expression level in caco-2 cancer cell line ( E ) BCL2 expression level in caco-2 cancer cell line ( F ) Cyclin D expression level in caco-2 cancer cell line.

Article Snippet: Primers for P53, BCL2 , Cyclin D, MMP9 and VEGF were purchased from Bioneer, Korea as shown in Table in supplementary materials.

Techniques: Expressing